Brief Article
Copyright ©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 14, 2012; 18(42): 6106-6113
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6106
Cost of treating chronic hepatitis B: Comparison of current treatment guidelines
Monica Robotin, Yumi Patton, Melanie Kansil, Andrew Penman, Jacob George
Monica Robotin, Yumi Patton, Andrew Penman, Medical and Scientific Issues Unit, Cancer Council NSW, 153 Dowling St, Wooloomooloo, Sydney 2011, Australia
Monica Robotin, School of Public Health, University of Sydney, Sydney 2006, Australia
Melanie Kansil, Cathedral Street Partners, 1/96 Cathedral St, Woollomooloo, Sydney 2011, Australia
Jacob George, Faculty of Medicine, University of Sydney, Sydney 2006, Australia
Jacob George, Storr Liver Unit, Westmead Millennium Institute Westmead Hospital, Sydney 2145, Australia
Author contributions: Robotin M designed the study and wrote the manuscript; Patton Y and Kansil M carried out the economic modeling; Kansil M developed the economic model; Robotin M, Penman A and George J contributed to economic model development; Penman A provided intellectual input and financial support for the study; George J was involved in editing the manuscript and overseeing the study.
Supported by A Cancer Council NSW grant, to George J; the Robert W Storr bequest to the Sydney Medical Foundation; and grants from the NHMRC
Correspondence to: Dr. Monica Robotin, Medical and Scientific Issues Unit, Cancer Council NSW, PO Box 572, Kings Cross NSW 1340, Sydney 2011, Australia. monicar@nswcc.org.au
Telephone: +61-2-93341900 Fax: +61-2-93680711
Received: April 13, 2012
Revised: August 1, 2012
Accepted: August 26, 2012
Published online: November 14, 2012
Abstract

AIM: To compare program costs of chronic hepatitis B (CHB) screening and treatment using Australian and other published CHB treatment guidelines.

METHODS: Economic modeling demonstrated that in Australia a strategy of hepatocellular cancer (HCC) prevention in patients with CHB is more cost-effective than current standard care, or HCC screening. Based upon this model, we developed the B positive program to optimize CHB management of Australians born in countries of high CHB prevalence. We estimated CHB program costs using the B positive program algorithm and compared them to estimated costs of using the CHB treatment guidelines published by the Asian-Pacific, American and European Associations for the Study of Liver Disease (APASL, AASLD, EASL) and those suggested by an independent United States hepatology panel. We used a Markov model that factored in the costs of CHB screening and treatment, individualized by viral load and alanine aminotransferase levels, and calculated the relative costs of program components. Costs were discounted by 5% and calculated in Australian dollars (AUD).

RESULTS: Using the B positive algorithm, total program costs amount to 13 979 224 AUD, or 9634 AUD per patient. The least costly strategy is based upon using the AASLD guidelines, which would cost 34% less than our B positive algorithm. Using the EASL and the United States Expert Group guidelines would increase program costs by 46%. The largest expenditure relates to the cost of drug treatment (66.9% of total program costs). The contribution of CHB surveillance (20.2%) and HCC screening and surveillance (6.6%) is small - and together they represent only approximately a quarter of the total program costs.

CONCLUSION: The significant cost variations in CHB screening and treatment using different guidelines are relevant for clinicians and policy makers involved in designing population-based disease control programs.

Keywords: Chronic hepatitis B; Markov model; Hepatocellular cancer; Treatment guidelines